MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

HELP ELIGIBLE PATIENTS **RECEIVE UP TO $4,000 EACH YEAR** FOR OUT-OF-POCKET EXPENSES

LEARN HOW TO ENROLL YOUR PATIENTS IN THE MYOBLOC COPAY PROGRAM TODAY!

INDICATIONS

MYOBLOC® injection is indication for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

Please see full Prescribing Information and additional Important Safety Information on the last page.

MYOBLOC COPAY PROGRAM

Eligibility criteria

Patients who:

- Are 18 years or older and a legal U.S. resident
- Have commercial insurance coverage
- Are diagnosed with cervical dystonia (CD) G24.3 or sialorrhea K11.7
- Are NOT enrolled in a government insurance plan (eg, Medicare, Medicaid, TRICARE®, and other federal- or state-funded programs)

Three ways to enroll patients

1. Patients will be automatically enrolled, if eligible, when the HCP utilizes the MYOBLOC Reimbursement Services Hub for benefit investigations
2. HCP staff may enroll patients by calling 1-888-461-2255, Option 3
   - Patient eligibility is verified in accordance with the MYOBLOC Copay Program guidelines
   - **The following information is required to complete enrollment:**
     - Patient demographics
     - Patient insurance information
     - Prescribing HCP information
3. Patients may enroll themselves by calling 1-888-461-2255, Option 3
   - No enrollment forms needed
   - No financial requirements

What's covered

- **CD or Sialorrhea:** J0587 – MYOBLOC
- **CD:** 64616 – Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)
- **Sialorrhea:** 64611 – Chemodenervation of parotid and submandibular salivary glands, bilateral
- **Injection guidance:**
  - **CD:** 95873 – Electrical stimulation for guidance in conjunction with chemodenervation
  - **CD:** 95874 – Needle electromyography for guidance in conjunction with chemodenervation
  - **CD or Sialorrhea:** 76942 – Ultrasonic guidance for needle placement imaging
  - *Note: Residents of Michigan, Rhode Island, and Minnesota are not eligible for injection procedure or injection guidance costs*

Please see full Prescribing Information, including boxed WARNING, and additional Important Safety Information on the last page.

MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

Patient is enrolled and approved. What's next?

Payment to office on patient's behalf for MYOBLOC, procedure, and guidance costs

1. Administer MYOBLOC for CD or chronic sialorrhea per PI*
2. File commercial insurance claim for services rendered
3. Once an Explanation of Benefits (EOB) is received from the commercial payer, fax EOB to 1-888-343-3275 or upload via the Circle of Care™ Provider Portal
4. Payment will be processed and funds will be available via virtual credit card or paper check within 2 business days from the receipt of complete documentation

Payment to office on patient's behalf for procedure and guidance costs. MYOBLOC payment to Specialty Pharmacy (SP)

1. Order product from SP
2. HCP provides Rx and BIN number to SP that was assigned to patient at time of enrollment
3. Administer MYOBLOC for CD or chronic sialorrhea per PI*
4. File commercial insurance claim for services rendered
5. Once an EOB is received from the commercial payer, fax EOB to 1-888-343-3275 or upload via the Circle of Care™ Provider Portal
6. Payment will be processed and funds will be available via virtual credit card or paper check within 2 business days from the receipt of complete documentation

Payment to patient for reimbursement of services paid to the provider

1. Administer MYOBLOC for CD or chronic sialorrhea per PI*
2. File commercial insurance claim for services rendered
3. Once an EOB is received from the commercial payer, fax EOB to 1-888-343-3275
4. Payment will be processed and a paper check will be mailed to the patient within 3 to 4 weeks from the receipt of complete documentation

***Please see DOSAGE AND ADMINISTRATION section in the PI for complete instructions.**

Terms and Conditions for Healthcare Providers:

1. This offer is valid for commercially insured patients only and is good for use only with a MYOBLOC prescription at the time the prescription is filled or after the product is administered to the patient. **2.** Depending on insurance coverage, eligible, insured patients may pay no more than zero dollars ($0) for MYOBLOC and the administrative services associated with MYOBLOC, up to a maximum savings limit of four thousand dollars ($4,000) per year. Patient out-of-pocket expense may vary. **3.** This offer is not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or private indemnity or HMO insurance plans that reimburse your patient for the entire cost of his/her prescription drugs. Patients may not use this Program if they are Medicare-eligible and enrolled in an employer-sponsored health plan or medical or prescription drug benefit program for retirees. **4.** The offer is valid for one (1) year. **5.** Supernus Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice. **6.** Offer good only in the USA, including Puerto Rico, at participating pharmacies or healthcare providers. **7.** Void if prohibited by law, taxed, or restricted. **8.** Residents of Michigan, Rhode Island, and Minnesota are not eligible for assistance with payment for injection or injection guidance-related costs, but may receive assistance with MYOBLOC. **9.** This Program is not transferable. The selling, purchasing, trading, or counterfeiting of this Program is prohibited by law. **10.** This Program is not insurance. **11.** By redeeming this assistance, you represent that, to the best of your knowledge, the patient is eligible to participate in the Program and that you understand and agree to comply with the terms and conditions of this offer.

IMPORTANT SAFETY INFORMATION (cont'd)

CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:

- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

- **Lack of Interchangeability Between Botulinum Toxin Products**
  The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.
- **Hypersensitivity Reactions**
  Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.
- **Dysphagia and Breathing Difficulties**
  Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.
  - **Cervical Dystonia:** Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.
  - **Pre-Existing Neuromuscular Disorders:** Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC.
- **Human Albumin and Transmission of Viral Diseases**
  This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

MOST COMMON ADVERSE REACTIONS (>5% OF PATIENTS AND >5% MORE THAN PLACEBO)

Cervical Dystonia: dry mouth, dysphagia, injection site pain, headache
Chronic Sialorrhea: dry mouth, dysphagia

DRUG INTERACTIONS

Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of MYOBLOC may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of MYOBLOC.

Please see full Prescribing Information, including Boxed WARNING.

MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

myobloc.com

Supernus® Pharmaceuticals